Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Terminated

Phase 0 Results N/A

Trial Description

The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.

Trial Stopped: Principle Investigator is moving to another institution and plans to restart this proctocol in the new location.

Conditions

Interventions

  • Placebo Drug
    Intervention Desc: normal saline IV for 4 hours for 5 consecutive days
    ARM 1: Kind: Experimental
    Label: placebo
    Description: normal saline IV for 4 hours for 5 consecutive days
  • Desferrioxamine (DFO) Drug
    Other Names: deferoxamine, desferal, DFO, deferoxamine mesylate
    Intervention Desc: DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
    ARM 1: Kind: Experimental
    Label: Desferrioxamine (DFO)
    Description: DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Outcomes

Type Measure Time Frame Safety Issue
Primary delayed cerebral ischemia (DCI) 6 weeks post hemorrhage No
Secondary Clinical outcome at discharge patient's discharge date, which averages 3-4 weeks post hemorrhage No

Sponsors